Brainomix 360, an AI-enabled software, has recently been endorsed by the National Institute of Health and Care Excellence (NICE). This endorsement, published in NICE’s guidance, recognizes the software’s impact on clinical decision-making for stroke patients.
Formerly known as e-Stroke, Brainomix was one of only two companies granted this endorsement, which is expected to expand access to life-changing treatment for more stroke patients. The platform has been elevated to an evidence generation framework, allowing stroke units across the UK to use the technology while further evidence is collected.
The Health Technology Assessment has acknowledged evidence that patients admitted to hospitals with a suspected stroke received faster and improved access to treatment after using Brainomix 360. Further collection of evidence and data on the cost-effectiveness of the platform will validate this link.
Dr. Michalis Papadakis, co-founder and CEO of Brainomix, expressed his satisfaction with the NICE endorsement, emphasizing the critical role of the AI-powered software in stroke care and its impact on treatment decisions. Real-world evidence has demonstrated the transformative impact of Brainomix 360, particularly in mechanical thrombectomy.
A report by Health Innovation Oxford & Thames Valley revealed that hospitals using Brainomix 360 software had an average thrombectomy treatment rate 55% higher than the national average, leading to hundreds more patients receiving life-changing treatment.
Dr. Kiruba Nagaratnam, consultant stroke physician and clinical lead for stroke medicine at the Royal Berkshire Hospital in Reading, welcomed the latest guidance from NICE, highlighting the clinical value of Brainomix 360 in stroke care. A recently published study showed improved speed of treatment and patient outcomes with the implementation of Brainomix 360.
